1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Co., Ltd.
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO CO., LTD.

(4568)
  Report
Delayed Japan Exchange  -  05/24 02:00:00 am EDT
3370.00 JPY   -0.79%
05/19Jacobs Wins Deal to Support Clean-Up of Japan's Fukushima Nuclear Plant
MT
05/17LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
AQ
05/05AstraZeneca, Daiichi Sankyo Say US FDA Clears Enhertu to Treat Breast Cancer; AstraZeneca's Ultomiris Meets Primary Endpoint
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo Company, Limited Revises Earnings Guidance for the Full Year 2022

10/29/2021 | 02:30am EDT

Daiichi Sankyo Company, Limited revised earnings guidance for the full year 2022. The company expected revenue to grow due to good performance in products such as Lixiana and Injectafer and also due to ForEx impact. Therefore, the company has made an upward revision of forecast announced in April by JPY 40 billion to JPY 1.30 billion. As a result, the company has made an upward revision of core operating profit forecast by JPY 20 billion to JPY 90 billion. Operating profit forecast has been revised upward by JPY 22 billion to JPY 92 billion as booked as temporary income gains related to sale of Osaka Logistics Center in fiscal year 2020,211th quarter. Based on the upward revision of operating profit and pretax profit numbers, the company's forecast of profit attributable to owners of the company has been revised upward by JPY 14 billion or to JPY 64 billion.


© S&P Capital IQ 2021
All news about DAIICHI SANKYO CO., LTD.
05/19Jacobs Wins Deal to Support Clean-Up of Japan's Fukushima Nuclear Plant
MT
05/17LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recen..
AQ
05/05AstraZeneca, Daiichi Sankyo Say US FDA Clears Enhertu to Treat Breast Cancer; AstraZene..
MT
05/05Enhertu approved in the US for patients with HER2-positive metastatic breast cancer tr..
AQ
05/05AstraZeneca, Daiichi's Breast Cancer Treatment Wins US Approval
MT
05/05AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment
DJ
04/28ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in t..
AQ
04/28AstraZeneca - Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo's ..
AQ
04/28Daiichi Sankyo's FY22 Attributable Profit Falls 12% on Higher Expenses
MT
04/27SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Wednesday
MT
More news
Analyst Recommendations on DAIICHI SANKYO CO., LTD.
More recommendations
Financials
Sales 2022 1 035 B 8 099 M 8 099 M
Net income 2022 70 466 M 552 M 552 M
Net cash 2022 497 B 3 890 M 3 890 M
P/E ratio 2022 92,3x
Yield 2022 0,79%
Capitalization 6 460 B 50 565 M 50 565 M
EV / Sales 2022 5,76x
EV / Sales 2023 5,21x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO CO., LTD.
Duration : Period :
Daiichi Sankyo Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 3 370,00 JPY
Average target price 3 942,86 JPY
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Executive Officer & Head-Corporate Planning
Wataru Takasaki Head-Research & Development
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO CO., LTD.16.14%50 970
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY9.55%272 388
ABBVIE INC.9.33%261 585